Treatment of Paragangliomas with Lutetium-177-Octreotate Based Peptide Receptor Radionuclide Therapy

#1904

Introduction: Paragangliomas (PGL) are a heterogeneous group of rare tumours that can express high numbers of somatostatin receptors on their cell surface and can be targeted with peptide receptor radionuclide therapy (PRRT) using the radiolabelled somatostatin analogue [lutetium-177-DOTA-Tyr3-]octreotate (177Lu-octreotate).

Aim(s): To report safety and efficacy.

Materials and methods: From a larger cohort treated with PRRT, all Dutch patients with histologically proven inoperable or metastatic PGL were selected. The intended dose of 177Lu-octreotate was 4x 7.4 GBq, administered with intervals of 6-12 weeks. Data were prospectively registered, Kaplan-Meier analysis was used to express survival.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Smit Duijzentkunst D

Authors: Smit Duijzentkunst D, Kwekkeboom D,

Keywords: PRRT, paragangliomas,